Clinical Trials

153 enrolled

Leukemia, Myeloid, Acute

NCT06317662 2026-04-16

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

153 enrolled

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute

NCT05564390 2026-04-15

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

2,000 enrolled

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT05886049 2026-04-15

Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene

28 enrolled

Acute Myeloid Leukemia With KMT2A Rearrangement

NCT05554406 2026-04-14

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

335 enrolled

Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT06124157 2026-04-14

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

222 enrolled

Lymphoid

Burkitt Lymphoma

NCT01627041 2026-04-13

Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia

178 enrolled

Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Basophilic, Acute, Leukemia, Myelomonocytic, Acute

NCT04214249 2026-04-13

BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia

49 enrolled 32 charts

Phase 1 Active not recruiting

Leukemia, Myeloid, Acute

NCT05453903 2026-04-13

A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies

196 enrolled

Phase 2 Not yet recruiting

Leukemia, Myeloid, Acute

NCT05554419 2026-04-13

Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)

184 enrolled

Leukemia, Myeloid, Acute

NCT05955261 2026-04-13

A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia

Phase 2 Suspended

70 enrolled

Leukemia, Myeloid, Acute

NCT07007312 2026-04-09

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

1,300 enrolled

Leukemia, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT03150693 2026-04-07

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Phase 3 Suspended

310 enrolled

Lymphoid

Burkitt Lymphoma

NCT07223814 2026-04-06

Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

875 enrolled

Leukemia, Myeloid, Acute

NCT03959085 2026-03-31

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

5,951 enrolled

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Biphenotypic, Acute

NCT06578247 2026-03-31

QuANTUM-WILD

700 enrolled

Leukemia, Leukemia, Myeloid, Acute

NCT06313437 2026-03-25

Revumenib in Combination With 7+3 + Midostaurin in AML

22 enrolled

Phase 3 Not yet recruiting

Leukemia, Leukemia, Myeloid, Acute

NCT07407140 2026-03-25

VAG-3+7-G

300 enrolled

Leukemia, Myeloid, Acute

NCT02971397 2026-03-23

Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase 1 Completed

40 enrolled 21 charts

Phase 3 Active not recruiting

Leukemia, Myeloid, Acute

NCT02845882 2026-03-18

LBL-2016 for Children or Adolescents in China

150 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06918431 2026-03-17

Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

53 enrolled

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03591510 2026-03-13

A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML

22 enrolled

Leukemia, Myeloid, Acute

NCT05735184 2026-03-13

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Other hematologic neoplasmSarcoma

420 enrolled

Leukemia, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Sarcoma, Myeloid

NCT05627232 2026-03-12

Tazemetostat and Palbociclib With CPX-351for R/R AML

24 enrolled

Leukemia, Myeloid, Acute

NCT04231851 2026-03-06

CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia

30 enrolled 15 charts

Leukemia, Myeloid, Acute

NCT05157971 2026-03-05

Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia

Phase 2/3 Not yet recruiting

24 enrolled

Lymphoid

Burkitt Lymphoma

NCT07255872 2026-03-05

A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia

216 enrolled

Leukemia, Myeloid, Acute

NCT06289673 2026-03-03

Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma

Phase 4 Recruiting

850 enrolled

Leukemia, Biphenotypic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07132684 2026-03-02

Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients

240 enrolled

Leukemia, Myeloid, Acute

NCT06390319 2026-02-27

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

100 enrolled

Leukemia, Biphenotypic, Acute, Lymphoma, T-Cell, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04293562 2026-02-24

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

1,186 enrolled

Phase 3 Active not recruiting

Leukemia, Myeloid, Acute

NCT03007147 2026-02-23

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

475 enrolled

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT03629171 2026-02-20

Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia

52 enrolled

Leukemia, Myeloid, Acute

NCT04915612 2026-02-20

Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia

Phase 1 Completed

1 enrolled

Leukemia, Myeloid, Acute

NCT03826992 2026-02-18

Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia

21 enrolled

Leukemia, Recurrence, Leukemia, Myeloid, Acute

NCT06533748 2026-02-12

Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma

128 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02523976 2026-02-11

Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Phase 2 Completed

30 enrolled

Leukemia, Philadelphia Chromosome, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05656248 2026-02-04

Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms

25 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Juvenile

NCT03164057 2026-01-28

A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia

206 enrolled

Phase EARLY_PHASE1 Completed

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03568994 2026-01-27

ATACC AML

26 enrolled

Leukemia, Myeloid, Acute

NCT07228273 2026-01-22

Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia

102 enrolled

Phase 2/3 Active not recruiting

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03701308 2026-01-21

Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy

267 enrolled 11 charts

Phase 1 Active not recruiting

Leukemia, Myeloid, Acute

NCT03709758 2026-01-16

Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML

50 enrolled

Leukemia, Myeloid, Acute

NCT05342584 2026-01-08

Venetoclax AML

99 enrolled

Phase 2/3 Not yet recruiting

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT07072585 2025-12-31

Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)

1,708 enrolled

Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04659616 2025-12-19

Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia

32 enrolled

Leukemia, Myeloid, Acute

NCT04802161 2025-12-19

Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes

50 enrolled 12 charts

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT02881086 2025-12-16

Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment

Phase 3 Completed

1,023 enrolled

Phase 2/3 Active not recruiting

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03117751 2025-12-05

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

790 enrolled

Leukemia, Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05361057 2025-12-05

Efficacy of Venetoclax Based Regimen in Prevention Relapse of Consecutive MRD Positive AML Patients

Phase 2 Terminated

20 enrolled